| HOME >> BIOLOGY >> TECHNOLOGY |
GAAP Adjustments Basis(a)
Net revenue $287,960 $- $287,960
Cost of sales 149,209 (13,266)(b)(c)(d)(f) 135,943
Gross profit 138,751 13,266 152,017
Gross margin 48% 53%
Operating expenses:
Research and
development 24,898 (3,838)(b)(c)(d) 21,060
Purchase of in-process
research and
development 4,825 (4,825)(g) -
Selling, general and
administrative 99,758 (19,658)(b)(c)(d) 80,100
Loss on dispositions,
net - - -
Operating income 9,270 41,587 50,857
Interest and other income
(expense), net (25,146) 4,006(c)(h) (21,140)
Income tax (benefit)
provision (3,366) 5,494(i) 2,128
Net (loss) income $(12,510) $40,099 $27,589
Net (loss) income per
common share:
Basic $(0.19) $0.42
Diluted $(0.19)(j) $0.40(k)
Weighted average common
shares - basic 65,525 65,525
Weighted average common
shares - diluted 65,525(j) 69,578(k)
Three Months Ended December 31, 2006
Non-GAAP
Adjusted
Non-GAAP Cash
'/>"/>
| SOURCE Inverness Medical Innovations Copyright©2008 PR Newswire. All rights reserved |